GET DAILY SIGNALSCoya Therapeutics (COYA) Stock Drops -32.6% in 30 Days: Earnings Miss and Cash Concerns Weigh on Shares
Key Takeaways
- Coya Therapeutics (COYA) declined roughly 32.6% over the trailing 30 days, falling from about $4.81 to near $3.24.
- The slide was driven primarily by third-quarter 2026 results that missed earnings estimates, alongside widening operating losses and a shrinking cash balance.
- Positive clinical progress, including the completed full enrollment of the ALSTARS Phase 2/3 ALS trial, was overshadowed by cash-burn and dilution concerns.
- Over the trailing quarter, the stock is down roughly 32.5%, reversing a late-September rally that peaked near $5.30.
- Topline data from the 24-week double-blind treatment phase of the ALSTARS trial is anticipated in early Q2 2027.
Coya Therapeutics (COYA) Company Overview and Market Position
Coya Therapeutics, Inc. is a Houston, Texas-based clinical-stage biotechnology company developing proprietary therapies built around the biology of regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. Its therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
The company's lead candidate, COYA 302, is an investigational combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig designed to restore Treg function while suppressing inflammation from activated monocytes and macrophages. It is being evaluated for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), among other neurodegenerative conditions. COYA 302 has received FDA Fast Track designation for ALS. Investors follow COYA primarily for the progress of its clinical pipeline and its ability to fund development through late-stage data readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Coya Therapeutics (COYA) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, COYA fell from a closing price of approximately $4.81 on October 12 to around $3.24, a decline of roughly 32.6%. The move was not linear: shares drifted lower through mid-October before a sharp acceleration in late October and early November, reaching an intraday low near $2.74 on November 5 before a modest rebound.
The trailing quarter tells a similar story on a broader timeline. From a close near $4.80 in early August, the stock is down about 32.5%. During the quarter, COYA briefly rallied to a peak around $5.30 in late September before reversing, giving back those gains and then some. The net result has been a sustained downtrend, with the stock trading well below its 52-week high. From what I see, this pattern aligns with how clinical-stage biotechs often react to financial updates.
What Drove COYA Stock Price in the Last 30 Days
The most consequential catalyst in the 30-day window was the company's third-quarter 2026 financial report, released in early November. Coya posted a GAAP loss of $0.45 per share, missing analyst estimates by roughly $0.11, while reporting collaboration revenue of about $0.23 million. The wider-than-expected loss reflected a substantial increase in operating expenses and a significantly expanded loss from operations compared with the prior-year period.
Investor attention also focused on the balance sheet. Cash and cash equivalents declined to approximately $35.8 million as of September 30, 2026, down from about $46.8 million at the end of 2025. While management has guided that its cash runway extends into the second half of 2027, ongoing cash burn and the prospect of future financing created overhang for a clinical-stage company with no marketed products.
The decline was compounded by profit-taking after a late-September rally, and by broader risk-off sentiment that weighed on speculative, pre-revenue biotech names. Notably, positive pipeline developments during the period, including the completion of full enrollment in the ALSTARS trial and the initiation of an open-label extension, did not offset the negative earnings and cash-burn narrative. I’m watching this closely as the financial metrics continue to influence sentiment.
What Drove COYA Stock Performance Over the Last Quarter
The quarterly trend reflects a broader repricing of risk around Coya's clinical-stage profile. Shares strengthened through September as the company reported the enrollment of its 100th participant and, later, full enrollment of the ALSTARS Phase 2/3 trial, with topline data guided for early Q2 2027. That momentum briefly pushed the stock above $5.
However, the upward move was not sustained. As the quarter progressed, investors refocused on the company's rising operating costs, widening net losses, and declining cash reserves. The third-quarter earnings miss in early November crystallized those concerns and accelerated the selloff. The quarter's overall decline highlights how, for pre-revenue biotechnology companies, clinical execution must be weighed against financial runway and the likelihood of additional capital raises.
COYA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the single most important catalyst is the topline readout from the 24-week double-blind treatment phase of the ALSTARS Phase 2/3 trial, anticipated in early Q2 2027. Results here will be central to validating COYA 302's clinical profile in ALS.
Investors should also monitor the initiation and enrollment of the planned Phase 2 study of COYA 302 in frontotemporal dementia, additional biomarker and proteomics data from investigator-initiated studies, and any updates on the company's manufacturing and partnership arrangements. Financial execution remains equally important: quarterly cash burn, the timing and terms of any future financings, and the pace of operating expense growth will shape sentiment. As always with clinical-stage biotech, regulatory updates and clinical data carry outsized influence on the share price. One thing that stands out is how these factors often interact in ways that surprise even experienced observers.
Exploring AI-Driven Trading Strategies
In my own analysis, I frequently review Tickeron’s Trending AI Robots to see how automated strategies are positioning around names like this. The platform highlights a range of bots with different approaches and timeframes, which helps put the recent volatility in context without replacing core fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
COYA sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where COYA's RSI Oscillator exited the oversold zone, 27 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.498). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement